Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Study to Evaluate NOE-101 (an mGluR5 inhibitor) for the Treatment of Persistent Seizures in Tuberous Sclerosis Complex (TSC)

Next Previous
Trial Profile

A Phase 2b Study to Evaluate NOE-101 (an mGluR5 inhibitor) for the Treatment of Persistent Seizures in Tuberous Sclerosis Complex (TSC)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Basimglurant (Primary)
  • Indications Seizures; Tuberous sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 11 Dec 2024 According to Noema Pharma media release, the company extends Series B financing round, closing at CHF 130 Million ($147 Million).The financing will support this trial and key data readouts anticipated in 2025
  • 09 Dec 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top